# Ustekinumab

## Stelara inj 45mg/0.5mL

##### 臨採

| TAH Drug Code      | [ISTE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISTE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Treatment of adult patients with active psoriatic arthritis. Can be used alone or in combination with methotrexate (MTX). Treatment of adult patients with moderately to severely active Crohn’s disease. Treatment of adult patients with moderately to severely active ulcerative colitis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Plaque psoriasis (Moderate to Severe) (100 kg or less) 45 mg SC initially and 4 weeks later, followed by 45 mg every 12 weeks (Greater than 100 kg) 90 mg SC initially and 4 weeks later, followed by 90 mg every 12 weeks Psoriatic arthritis 45 mg SC initially and 4 weeks later, followed by 45 mg SC every 12 weeks Coexistent moderate to severe plaque psoriasis and weight greater than 100 kg, 90 mg SC initially and 4 weeks later, followed by 90 mg SC every 12 weeks Crohn's disease & Ulcerative colitis (Moderate to Severe) (55 kg or less) Induction, 260 mg (two 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 55 kg to 85 kg) Induction, 390 mg (three 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 85 kg) Induction, 520 mg (four 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg SC every 8 weeks beginning 8 weeks after induction dose |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients. Clinically important, active infection .                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common Dermatologic: Erythema at injection site (1% to 5% ), Pruritus (1% to 4% ) Gastrointestinal: Abdominal pain (7% ), Diarrhea (2% to 4% ), Nausea (3% ), Vomiting (4% ) Neurologic: Headache (5% to 10% ) Renal: Urinary tract infectious disease (4% ) Reproductive: Mycosis (Crohn disease, 5% ) Respiratory: Bronchitis (5% ), Nasopharyngitis (7% to 24% ), Sinusitis (3% to 4% ), Upper respiratory infection (4% to 5% ) Other: Fatigue (3% to 4% ), Fever (5% ), Infectious disease (Psoriasis, 27% to 72.3% ) Serious Dermatologic: Skin cancer, Non-melanoma (Up to 1.5% ) Gastrointestinal: Diverticulitis (Less than 1% ) Immunologic: Anaphylaxis (Crohn disease, 0.1% ), Hypersensitivity reaction (Crohn disease, 0.08% ) Neurologic: Posterior reversible encephalopathy syndrome Ophthalmic: Herpes zoster with ophthalmic complication (Less than 1% ) Respiratory: Cryptogenic organizing pneumonia, Interstitial pneumonia, Pulmonary eosinophilia Other: Angioedema, Cancer (Up to 1.7% ), Infectious disease, Serious (Up to 2.8% )                                                     |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

## STELARA inj 90mg/1mL

##### 臨採

| TAH Drug Code      | [ISTE9](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISTE9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Treatment of adult patients with active psoriatic arthritis. Can be used alone or in combination with methotrexate (MTX). Treatment of adult patients with moderately to severely active Crohn’s disease. Treatment of adult patients with moderately to severely active ulcerative colitis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Plaque psoriasis (Moderate to Severe) (100 kg or less) 45 mg SC initially and 4 weeks later, followed by 45 mg every 12 weeks (Greater than 100 kg) 90 mg SC initially and 4 weeks later, followed by 90 mg every 12 weeks Psoriatic arthritis 45 mg SC initially and 4 weeks later, followed by 45 mg SC every 12 weeks Coexistent moderate to severe plaque psoriasis and weight greater than 100 kg, 90 mg SC initially and 4 weeks later, followed by 90 mg SC every 12 weeks Crohn's disease & Ulcerative colitis (Moderate to Severe) (55 kg or less) Induction, 260 mg (two 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 55 kg to 85 kg) Induction, 390 mg (three 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 85 kg) Induction, 520 mg (four 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg SC every 8 weeks beginning 8 weeks after induction dose |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients. Clinically important, active infection .                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common Dermatologic: Erythema at injection site (1% to 5% ), Pruritus (1% to 4% ) Gastrointestinal: Abdominal pain (7% ), Diarrhea (2% to 4% ), Nausea (3% ), Vomiting (4% ) Neurologic: Headache (5% to 10% ) Renal: Urinary tract infectious disease (4% ) Reproductive: Mycosis (Crohn disease, 5% ) Respiratory: Bronchitis (5% ), Nasopharyngitis (7% to 24% ), Sinusitis (3% to 4% ), Upper respiratory infection (4% to 5% ) Other: Fatigue (3% to 4% ), Fever (5% ), Infectious disease (Psoriasis, 27% to 72.3% ) Serious Dermatologic: Skin cancer, Non-melanoma (Up to 1.5% ) Gastrointestinal: Diverticulitis (Less than 1% ) Immunologic: Anaphylaxis (Crohn disease, 0.1% ), Hypersensitivity reaction (Crohn disease, 0.08% ) Neurologic: Posterior reversible encephalopathy syndrome Ophthalmic: Herpes zoster with ophthalmic complication (Less than 1% ) Respiratory: Cryptogenic organizing pneumonia, Interstitial pneumonia, Pulmonary eosinophilia Other: Angioedema, Cancer (Up to 1.7% ), Infectious disease, Serious (Up to 2.8% )                                                     |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

